RLYB · Rallybio Corp · Metrics
Market Cap
$88.26M
Shares
5.31M
Volume · Oct 5
4632
Avg daily vol (3M)
22.49K
RLYB metrics
52 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$17.08
Market cap
$88.26M
Price action
20 metricsPrice change (1W)
+2.8%
Price change (30D)
+2.8%
Price change (3M)
+8.0%
Price change (6M)
+102.6%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
97.2%
Annualized volatility (3M)
21.5%
Beta
0.3
RSI (14D)
54.0
Price vs SMA 50
+2.3%
Price vs SMA 200
—
Avg volume (3M)
22,769
Relative volume
0.3
Average dollar volume
$372,706
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
5.31M
Valuation
12 metricsP / E (TTM)
2.2
Trailing earnings · reciprocal yield 46.4%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
136.6×
reciprocal yield 0.7%
P / book
0.9
reciprocal yield 107.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
3.3
reciprocal yield 30.3%
Earnings yield
51.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-03-13
Profitability
9 metricsGross margin
—
Operating margin
-4,291.5%
Trailing 12 months
Net margin
7,051.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$27.72M
Net income (TTM)
$45.55M
Trailing 12 months
Diluted EPS (TTM)
$7.93
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$646,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
48.2%
Return on assets
46.5%
Debt / equity
—
Current ratio
27.3
EBITDA (TTM)
−$27.68M
Free cash flow (TTM)
—
Quick ratio
27.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$92.85M
Latest balance sheet
Cash & equivalents
$92.85M
Total assets
$98.06M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
$26.71M
Capital expenditures (TTM)
$12,000
R&D (TTM)
$11.43M
SG&A (TTM)
—
Stock compensation (TTM)
$2.86M
R&D / revenue
1,768.9%
Stock compensation / revenue
442.4%
Ownership (13F)
3 metrics13F filers
37
13F filer change QoQ
-1
Institutional ownership
76.6%
Short interest
3 metricsShort interest
1.0%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
49 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—